Form 4: Exagen Inc. Director Nova Acquires Stock Options
SEC Form 4 Filing
Director Tina Susan Nova acquired 13,500 stock options in Exagen Inc. on June 10, 2024, at an exercise price of $1.99.
Summary
- On June 10, 2024, Tina Susan Nova, a director of Exagen Inc., acquired 13,500 stock options.
- The exercise price of these options is $1.99.
- The options vest and become exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of Exagen's stockholders, contingent upon continued service on the board.
- Following the transaction, Nova directly owns 13,500 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports an insider transaction. It doesn't inherently indicate positive or negative performance for the company.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment as it shows a director increasing their stake in the company.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of transaction: Tina Susan Nova acquired stock options. |
| 06/09/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.